

Radmila Choate

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2653488/publications.pdf>

Version: 2024-02-01

28
papers

246
citations

1163117

8
h-index

996975

15
g-index

28
all docs

28
docs citations

28
times ranked

463
citing authors

#	ARTICLE	IF	CITATIONS
1	Stenotrophomonas maltophilia in patients with bronchiectasis: An analysis of the US bronchiectasis and NTM Research Registry. <i>Respiratory Medicine</i> , 2022, 193, 106746.	2.9	5
2	Pilot Study of a Patient Experience with an ELLIPTA Inhaler Electronic Medication Monitor and Associated Integrated System: A Prospective Observational Study Using the COPD Patient-Powered Research Network. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021, 8, 488-501.	0.7	2
3	Self-reported COPD Medication Use and Adherence in the COPD Foundation Patient- Powered Registry Network. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021, 8, 474-487.	0.7	2
4	<i>Pseudomonas aeruginosa</i> associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) study. <i>Respiratory Medicine</i> , 2021, 177, 106285.	2.9	7
5	The Association of Long-term Macrolide Therapy and Nontuberculous Mycobacterial Culture Positivity in Patients With Bronchiectasis. <i>Chest</i> , 2021, 160, 466-469.	0.8	4
6	Symptom Burden and Medication Use Among Patients with Nontuberculous Mycobacterial Lung Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2021, 8, 243-254.	0.7	3
7	PATIENT-REPORTED PULMONARY SYMPTOMS AND EXACERBATIONS IN A COHORT OF PATIENTS WITH ALPHA-1 ANTITRYPSIN DEFICIENCY. <i>Chest</i> , 2021, 160, A1793-A1794.	0.8	0
8	REFRACTORY NONTUBERCULOUS MYCOBACTERIAL PULMONARY DISEASE: DESCRIPTIVE ANALYSIS FROM THE UNITED STATES BRONCHIECTASIS AND NTM RESEARCH REGISTRY. <i>Chest</i> , 2021, 160, A508.	0.8	1
9	BASILINE CLINICAL CHARACTERISTICS OF ADULT NON-CYSTIC FIBROSIS BRONCHIECTASIS PATIENTS ON HIGH FREQUENCY CHEST WALL OSCILLATION AND OTHER AIRWAY CLEARANCE THERAPIES: ANALYSIS FROM THE UNITED STATES BRONCHIECTASIS RESEARCH REGISTRY. <i>Chest</i> , 2020, 158, A1697-A1698.	0.8	1
10	ASSESSMENT OF PATIENT INTERACTION WITH A DRY POWDER INHALER ELECTRONIC MEDICATION MONITOR AND INTEGRATED SYSTEM WITHIN THE COPD FOUNDATION PATIENT POWERED RESEARCH NETWORK. <i>Chest</i> , 2020, 158, A1745-A1746.	0.8	0
11	Airway Clearance Techniques in Bronchiectasis. <i>Chest</i> , 2020, 158, 1376-1384.	0.8	22
12	Nutrition and Markers of Disease Severity in Patients With Bronchiectasis. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 7, 390-403.	0.7	3
13	Home-Based Multicomponent Intervention Increases Exercise Activity and Improves Body Mass Index: Results of a 5-Year Randomized Trial Among Individuals with Alpha-1 Antitrypsin Deficiency-Associated Lung Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 8, 7-18.	0.7	2
14	The Burden of Cough and Phlegm in People With COPD: A COPD Patient-Powered Research Network Study. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2020, 7, 49-59.	0.7	8
15	PULMONARY REHABILITATION AWARENESS AND UPTAKE IN AN ENGAGED COHORT OF PEOPLE WITH COPD. <i>Chest</i> , 2019, 156, A900-A902.	0.8	0
16	Comparing Patients with ZZ Versus SZ Alpha-1 Antitrypsin Deficiency: Findings from AlphaNet™s Disease Management Program. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 29-39.	0.7	12
17	Patient-Reported Consequences of Community-Acquired Pneumonia in Patients with Chronic Obstructive Pulmonary Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 132-144.	0.7	9
18	The Clinical Features of Bronchiectasis Associated with Alpha-1 Antitrypsin Deficiency, Common Variable Immunodeficiency and Primary Ciliary Dyskinesia--Results from the U.S. Bronchiectasis Research Registry. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019, 6, 145-153.	0.7	21

#	ARTICLE	IF	CITATIONS
19	Comparison of outcomes in augmentation naïve and augmented patients with alpha-1 antitrypsin deficiency related lung disease. , 2019, , .		1
20	The Prevalence and Significance of <i>Staphylococcus aureus</i> in Patients with Non-Cystic Fibrosis Bronchiectasis. <i>Annals of the American Thoracic Society</i> , 2018, 15, 365-370.	3.2	36
21	National and State Estimates of COPD Morbidity and Mortality United States, 2014-2015. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2018, 5, 324-333.	0.7	65
22	1487: USE OF ARB-BICARBONATE SCORE TO PREDICT SITE OF CARE IN PATIENTS WITH SEPSIS. <i>Critical Care Medicine</i> , 2018, 46, 727-727.	0.9	0
23	Impact of donor lung pathogenic bacteria on patient outcomes in the immediate post-transplant period. <i>Transplant Infectious Disease</i> , 2018, 20, e12986.	1.7	17
24	Genotype is associated with smoking and other key health behaviors among individuals with alpha-1 antitrypsin deficiency-associated lung disease. <i>Respiratory Medicine</i> , 2018, 143, 48-55.	2.9	11
25	Frequency of untreated hypogammaglobulinemia in bronchiectasis. <i>Annals of Allergy, Asthma and Immunology</i> , 2017, 119, 83-85.	1.0	4
26	Utility of the Modified CRB Score in Predicting Site of Care and Disease Severity in Patients With Sepsis Presenting to the Emergency Department. <i>Chest</i> , 2017, 152, A411.	0.8	0
27	Benefits Among Patients with Alpha-1 Antitrypsin Deficiency Enrolled in a Disease Management and Prevention Program. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2017, 4, 56-64.	0.7	10
28	Red Cell Transfusion and Mortality of MICU Patients Receiving Continuous Renal Replacement Therapy. <i>Chest</i> , 2016, 150, 223A.	0.8	0